Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
International Journal of Cancer|June 15, 1990
Cytokinetic investigation of lung tumors using the anti-bromodeoxyuridine (BUdR) monoclonal antibody method: comparison with DNA flow cytometric dataL Teodori, M L Trinca, W Goehde, et al.
The International Journal of Artificial Organs|August 1, 1996
Arteriovenous fistula obstruction and expression of platelet receptors for von Willebrand factor and for fibrinogen (glycoproteins GPib and GPiib/iiia) in hemodialysis patientsM Liani, F Salvati, E Tresca, et al.
Tumori|January 1, 1995
Lonidamine plus cyclophosphamide in the treatment of adanced non-small cell lung cancer in the elderly: a phase II studyF Salvati, A Antilli, A R Cruciani, et al.
Oncology|January 1, 1992
Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours'C Bartoloni, L Guidi, A Tricerri, et al.
Cancer Detection and Prevention|January 1, 1985
Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stageF Salvati, A Antilli, A R Cruciani, et al.
European Journal of Epidemiology|January 1, 1992
Seroprevalence of antibodies to hantaviruses and leptospires in selected Italian population groupsM Nuti, D Amaddeo, G L Autorino, et al.
American Journal of Clinical Oncology|February 1, 1994
Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesotheliomaA Ardizzoni, M C Pennucci, B Castagneto, et al.
Cancer|July 1, 1990
Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task ForceR Rosso, F Salvati, A Ardizzoni, et al.
Oncology|January 1, 1988
Intrapleural natural beta interferon in the treatment of malignant pleural effusionsR Rosso, R Rimoldi, F Salvati, et al.
American Journal of Clinical Oncology|April 1, 1991
Combination chemotherapy and interferon alpha 2b in the treatment of advanced non-small-cell lung cancer. The Italian Lung Cancer Task Force (FONICAP)A Ardizzoni, R Rosso, F Salvati, et al.
Pageof 6